Rolke James 4
4 · LA JOLLA PHARMACEUTICAL CO · Filed Feb 19, 2020
Insider Transaction Report
Form 4
Rolke James
Chief Scientific Officer
Transactions
- Award
Common Stock
2020-02-14$7.14/sh+115$821→ 80,535 total - Award
Stock Option (Right to Buy)
2020-02-14+115→ 115 totalExercise: $8.40Exp: 2030-02-14→ Common Stock (115 underlying)
Footnotes (2)
- [F1]These shares were acquired on 02/14/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
- [F2]The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years.